3.2.1.25	(5R,6R,7S,8S)-5-(hydroxymethyl)-2-phenyl-5,6,7,8-tetrahydroimidazol[1,2-a]pyridine-6,7,8-triol	-	5366	
3.2.1.25	(5S,6R,8R)-5-(hydroxymethyl)-2-(2-phenylethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol	persuasive transition state mimic	66573	
3.2.1.25	(5S,6R,8R)-5-(hydroxymethyl)-2-(phenoxymethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol	persuasive transition state mimic	72817	
3.2.1.25	(5S,6R,8R)-5-(hydroxymethyl)-2-[(phenylamino)methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6,7,8-triol	persuasive transition state mimic	72818	
3.2.1.25	2-amino-2-deoxy-D-mannose	-	15479	
3.2.1.25	2-amino-2-deoxy-D-mannose	competitive	15479	
3.2.1.25	2-deoxy-2-fluoro-beta-D-mannosyl fluoride	time-dependent inactivation through accumulation of a covalent 2-deoxy-2-fluoro-alpha-D-mannosyl-beta-mannosidase 2A enzyme intermediate	55972	
3.2.1.25	2-deoxy-2-fluoro-beta-glycosyl fluorides	in vivo inhibition	102137	
3.2.1.25	4-nitrophenyl beta-D-thioglucoside	competitive, adopts 4NP-S-Glc 3S5 or 1S3 conformations upon binding according to STD NMR and trNOESY experiments. QM modeling and docking, based on GLIDE scores, predicts that 4-nitrophenyl beta-D-thioglucoside preferentially binds in 1S3 geometries	85280	
3.2.1.25	4-nitrophenyl beta-D-thiomannoside	competitive, adopts 4C1 geometry upon binding according to STD NMR and trNOESY experiments. QM modeling and docking, based on GLIDE scores, predicts that 4-nitrophenyl beta-D-thiomannoside preferentially binds in 1S3 geometries	85281